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Abstract
Background: Hypofractionated three-dimensional conformal radiation therapy (3D-CRT) is a treatment option for
patients with early-stage non-small cell lung cancer (NSCLC) who are medically unable to tolerate surgery and who
are not amenable to treatment with stereotactic body radiotherapy. This study assessed the efficacy and safety of
3D-CRT as a monotherapy in patients with localized stage T2 or T3 NSCLC.
Methods: This retrospective study consisted of 29 patients (20 males) aged 56–89 years (median, 76 years) with
histologically confirmed NSCLC who underwent 3D-CRT between 2005 and 2014.
Results: The median duration of patient observation was 17.0 months (range, 1.0–64.0 months). Complete and
partial responses occurred in 13.8 and 44.8 % of patients, respectively, and the overall response rate was 58.2 %.
Meanwhile, the 1- and 3-year survival rates were 65.8 and 33.8 %, respectively. In T2 NSCLC, the median survival
time (MST) was 12 months, and the 1- and 3-year survival rates were 62.4 and 21.4 %, respectively. In T3 NSCLC,
the MST was 17 months, and the 1- and 3-year survival rates were 72.9 and 48.6 %, respectively. Severe toxicities
(Common Terminology Criteria Grade 3) were not observed. The mean biologically effective dose required to
improve local control exceeded 80 Gy (range, 67.2–96.0 Gy).
Conclusion: These findings support a role for 3D-CRT as a treatment option for patients who refuse or could not
tolerate surgical therapy with early-stage NSCLC. Although this was a small, retrospective study, it may form the
basis for future, larger controlled studies on 3D-CRT as a monotherapy for NSCLC.
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Introduction
Three-dimensional conformal radiation therapy (3D-CRT)
delivers radiation to tumors while sparing surrounding
normal tissue structures. The use of patient-specific 3D
images allows for treatment planning in a manner that is
distinct from conventional radiotherapy techniques. The
complementary use of computed tomography (CT) and
magnetic resonance imaging (MRI) of the lungs is per-
formed to define the area of lung tumors. Identifying areas
of tumor and normal lung tissue allows for selective and
concentrated radiation therapy with less damage to nor-
mal lung tissue. Surgical resection is one treatment
method for localized non-small cell lung cancer (NSCLC),
and good outcomes are achieved with this method in stage
I or II NSCLC [1–3]. While surgery is recommended for
some patients with localized NSCLC, the proportion of
operable patients declines with age [4, 5]. Radiation ther-
apy is selected if pulmonary function is poor, if surgery is
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contraindicated due to the patient’s general condition, or
if the patient refuses surgery. However, satisfactory results
for patients with localized NSCLC have not been obtained
with conventional irradiation at a dose of 2 Gy given in a
single fraction [6–9]. In conventional radiation therapy,
therapeutic effects are obtained on the basis of differences
in the degrees of damage and recovery between normal
and cancer cells. Damage to normal cells can be reduced
by employing this irradiation method. Also, the treatment
duration is prolonged to increase the dose, which may in-
crease the risk of tumor regrowth. Further drawbacks in-
clude a low single radiation dose that reduces the anti-
tumor effects and changes in the characteristics of cancer
cells, especially their sensitivity to radiation, when the
treatment duration is prolonged. For this reason, the
duration of radiation treatment should be kept short,
and the radiation dose should be increased for im-
proved tumor control. Stereotactic body radiotherapy
(SBRT) has also been established as a treatment option
for localized NSCLC [10, 11]. SBRT results in improved
patient outcomes compared with conventional irradi-
ation, with results that rival surgery [12–14]. However,
SBRT requires greater precision and accuracy than con-
ventional radiotherapy, and it should be conducted ac-
cording to a strict protocol [15]. Furthermore, patient
characteristics such as tumor size, site, and general
physical condition can make performing SBRT difficult.
In such instances, hypofractionated 3D-CRT is an alterna-
tive treatment option [16, 17]. Some studies of hypofrac-
tionated radiotherapy (HFRT) using various radiation
dose schedules have reported improved outcomes beyond
those achieved with conventionally fractionated radiother-
apy [16–19]. High-dose irradiation with a biologically ef-
fective dose (BED) of 100 Gy or more enables good
localized disease control in SBRT, and thus, it may be
assumed that not necessarily a mere increase in the total
radiation dose, but increasing the BED as well will also
lead to good localized control in 3D-CRT [12]. Previous
reports indicated that when the radiation dose is increased
to 4 Gy delivered in a single fraction, there are no severe
adverse events and good localized control can be achieved
[20]. There are few reports that describe 3D-CRT to treat
patients with localized NSCLC without the use of com-
bined anticancer agents. At our institution, we have re-
cently administered radiation treatment to patients with
stage T2 or T3 NSCLC, in whom we increased the radi-
ation dose to more than 5 Gy delivered in a single fraction.
In these patients, the radiation field is defined as the
tumor plus margin, and the use of 3D-CRT is limited to
patients for whom elective nodal irradiation was not con-
ducted. This study investigated the safety and efficacy of
3D-CRTas a monotherapy in patients withT2 or T3 local-




This retrospective study included 29 patients (20 males)
aged 56–89 years (median, 76 years) with histologically
confirmed NSCLC who received hypofractionated 3D-
CRT between January 2005 and June 2014. Patients with
severe heart and lung disease who required regular oxygen
treatment were excluded. SBRT was indicated for patients
with peripheral lung malignancies measuring 3 cm or less
with a forced expiratory volume (FEV)1.0 of 800 ml or
more and a performance status (PS) of 0 to 1 and also for
patients with lung cancer located 2 cm or more from the
great vessels in the hilar region. Although there was no
strict age limit, a cut-off of 85 years was used as the upper
age limit for patients with PS 2. Even in patients who met
the indications for SBRT, 3D-CRT was selected when they
could not adequately synchronize respiration because le-
sions were located in the lower pulmonary lobes and there
was marked fluctuation.
When postoperative FEV1.0 was expected to be
800 ml or more, surgery was indicated in patients with
PS 0 to 1 and localized lung cancer without complica-
tions. Although combination treatment with anticancer
agents and radiation was the standard of care even for
patients lacking indications for SBRT or surgery, the
most common reason for selecting radiotherapy alone
was renal impairment, followed by patient refusal and
poor PS.
Staging investigations
Staging was performed using contrast-enhanced CT and
positron emission tomography (PET), according to the
recommendations of the current staging guidelines for
NSCLC [21]. Tumors located no more than 2 cm from
the pulmonary hilum were classified as the pulmonary
hilum type. In seven patients, staging was performed
using contrast-enhanced CT without PET. In addition to
standard blood tests, the presence of NSCLC tumor
markers was assessed, including monoclonal antibodies
to squamous cell carcinoma antigen, carcinoembryonic
antigen, and CYFRA 21.1 (a variant of cytokeratin 19)
[22]. Radiography of the chest, MRI of the brain, and
bone scintigraphy were performed. Staging, therapeutic
effect, and the presence or absence of recurrence were
determined by a radiologist, a respiratory medicine spe-
cialist, and a radiotherapist.
Radiation therapy
The treatment plan was performed with CT using a long
scan time (3 s). Tumor motion was accounted once at
the time of CT simulation. Scans were assessed in 3-mm
sections at the lesion site and 10-mm sections elsewhere.
The gross tumor volume was the volume of the area oc-
cupied by the tumor as measured by image diagnosis.
Sakaguchi et al. Radiation Oncology  (2016) 11:3 Page 2 of 8
However, because a long scan time was used, the clinical
target volume (CTV) was used to define the visible
range of CT. The internal target volume (ITV) was the
CTV plus the tumor margin for any organ movement.
The ITV included a 5–7 mm ‘set up’ margin to establish
the planning target volume (PTV). The radiation field
was defined as the PTV plus a 5-mm leaf margin. Using
a 6-MV X-ray beam, multifield irradiation to more than
four fields (all noncoplanar irradiation) was administered
under resting respiration. Each beam was created using
PTV along the path of the beam with a margin. Add-
itional techniques (for example field-in-field) were not
used. Intensity-modulated radiotherapy (IMRT) was not
used because our institution has no established policy of
applying this treatment modality in patients with lung
cancer. IMRT is not available in all institutions and is
used for lung cancer only at a limited number of institu-
tions. As 3D-CRT is an alternative treatment option for
patients who are not suitable candidates for SBRT, it is
reasonable to perform 3D-CRT at hospitals where SBRT,
including IMRT, is not available. Thus, we believe that
presenting data based on conventional 3D-CRT is both
important and clinically relevant. The superposition
method for the algorithm was used to calculate the irradi-
ation dose. The minimum and maximum doses according
to the PTV were 95 and 107 %, respectively (in the case of
a large PTV, delivering a minimum dose of 90 % was
acceptable). Elective nodal irradiation was not adopted for
all patients. More recently, as long as no respiratory
disturbance is present, irradiation is administered in our
center in a single fraction at a total dose of more than
5 Gy, irrespective of tumor site and size.
Evaluation of the initial clinical response and toxicity
All patients underwent routine X-ray imaging and tests
for serological tumor markers at 1 month after radio-
therapy and every 3 months thereafter. In the event of
poor X-ray results and positive tumor markers, a lung
CT was performed. Routine lung CT was performed
every 3–6 months following the completion of radiation
therapy. A complete response (CR) was defined as the
disappearance of all measurable disease and the ab-
sence of newly-developing lesions for 4 weeks. For
measurable disease, a partial response (PR) was defined
as a reduction in more than 30 % of the sum of the
cross-sectional diameters of all measurable lesions over
4 weeks. Progressive disease (PD) was defined as either
an increase of greater than 20 % of the sum of the
cross-sectional diameters of all assessable lesions in
4 weeks or the appearance of new lesions. Stable dis-
ease (SD) was determined when there was an insuffi-
cient increase in tumor size to qualify as PD. SD also
included the situation in which a tumor decreased in
size enough to no longer meet the definition of PD.
Responses were scored when the treatment was most
effective. Local recurrence was defined as changes simi-
lar to those of PD. When tumor growth was difficult to
assess because of radiation pneumonitis, tumor markers
measured each month were used as reference values,
and the date of recurrence was determined as the first
day when levels began to rise. Adverse events were de-
fined according to the Common Terminology Criteria
(CTC) for Adverse Events, version 4.0, with toxicity
graded as mild (CTC Grade 1), moderate (CTC Grade
2), severe (CTC Grade 3), or life-threatening (CTC
Grade 4) [23].
Statistical analysis
Overall survival was calculated as the interval from the
first day of treatment to the date of death or the last
follow-up before June 2014. If they reach the end of the
following period without having an event, patients were
censored. Local tumor control (LC) was calculated as
the period from the first day of treatment until local re-
lapse. Patients who died with no evidence of recurrence
were censored. Survival curves were generated using
Kaplan–Meier analysis. Univariate survival comparisons
were performed using the log-rank test. The analyzed
prognostic factors for survival were age (<75 vs. ≥75), PS
(≤1 vs. ≥2), T-stage (T2 vs. T3), location (lower lobe vs.
middle and upper lobes, near the pulmonary hilum vs.
peripheral), and pathology (squamous vs. adeno). Inde-
pendent variables that appeared statistically significant
on univariate analysis were tested by multivariate ana-
lysis. P < 0.05 indicated statistical significance. All calcu-
lations and survival displays were conducted using SPSS
15.0 J statistical software (SSPS Inc., Chicago, IL, USA).
Patient consent
The present study was a retrospective analysis of patient
diagnostic and treatment data. Written informed con-
sent was obtained from all patients, who were informed
that their data would be included in the study.
Results
Patient and treatment characteristics
Baseline patient characteristics are listed in Table 1.
Stage T2a NSCLC was present in 18 patients, whereas
nine patients were diagnosed with stage T3 disease
(thoracic invasion in eight patients and additional
tumor nodules in the same pulmonary lobe in one pa-
tient). SBRT was proactively performed in most pa-
tients with stage T1 disease, and these patients were
not included in the present study. The median tumor
diameter was 31 mm (range, 25–60 mm) in T2 cancer
and 42 mm (range, 26–60 mm) in T3 cancer. Tumors
near the hilum, i.e., those defined as being located
within 2 cm from the pulmonary hilum, were detected
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in 8 patients. Tumors growing in the lower lobes were
found in 11 patients. Dose fractionation was higher in
the most recent cases, with the highest dosage of 6 Gy
per fraction administered to two patients. The most
common dose was 5 Gy per fraction, administered to
15 patients. The treatment was given in three fractions
per week in one patient because of the patient’s general
condition, and all other patients received conventional
radiotherapy administered in a single fraction per day.
No patients underwent accelerated HFRT. To compare
the effects of different protocols with different fraction
sizes and total doses, the BED was adopted using a lin-
ear quadratic model. The α/β ratio was assumed to be
10 for acute effects on normal tissue and lung tumors.
The BED ranged from 67.2 to 96.0 Gy. The median
BED was approximately 80 Gy. When 80 Gy was used
as a cut-off value, BED was less than 80 Gy in 14 pa-
tients and more than 80 Gy in 15 patients.
Patient survival, response, and tumor recurrence
The median duration of observation was 17 months
(range, 1–64 months). CRs and PRs were recorded in
four (13.8 %) and 13 patients (44.8 %), respectively. SD
occurred in four patients (13.8 %), and PD occurred in
eight patients (27.6 %). The overall response rate was
58.6 %. The 1- and 3-year overall survival rates were
65.8 and 33.8 %, respectively (Fig. 1). There was no sig-
nificant difference in OS between patients with T2 and
Table 1 Clinical characteristics of patients
Characteristics Number
Patients 29














Location of the tumor 1
lower lobe 11
middle, upper lobe 18
Location of the tumor 2





Dose (Gy), median (range) 60 (48–60)
48Gy, 3Gy/f 1
50Gy, 5Gy/f 3



















Abbreviations: BED biological effective dose
Fig. 1 The median survival time following radiotherapy with
three-dimensional conformal radiation therapy was 17 months
(range, 1–64 months), and the estimated 3-year survival rate
was 38 %
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T3 (Fig. 2). The 1- and 3-year survival rates and prog-
nostic factors identified by univariate analysis are listed
in Table 2. However, there were no significant differ-
ences observed for any factors. During the follow-up, 11
patients died. The causes of death were primary disease
in seven patients, brain metastasis in two, other diseases
in two, and unknown in one. The 1- and 3-year cause-
specific survival rate was 77.3 % and 49.7 %, respectively.
Local tumor recurrence was observed in eight patients
(two patients’ imaging evaluation was difficult due to radi-
ation pneumonitis, and local recurrence was identified by
elevated tumor markers without metastasis to other sites)
and the 1-year LC rate was 66.1 %. Upon univariate ana-
lysis, the BED (≥80 Gy vs. <80 Gy) and performance status
(≤1 vs. ≥2) were significantly related to LC. Figures 3 and
4 illustrate the LC curves for NSCLC for each patient
group. Upon multivariate analysis, only BED was a sig-
nificant factor for LC (P = 0.037; hazard ratio = 10.10;
95 % confidence interval = 1.150–88.67) (Table 3).
Radiation toxicity
Among acute toxicities, grade 1 pneumonitis was observed
in three patients who received irradiation at a BED of
80 Gy or more and in two patients with a BED of less than
80 Gy. No patient was given oral steroid treatment or oxy-
gen therapy. No patient developed esophagitis or macro-
vascular disease. No severe adverse events were observed.
Discussion
This retrospective study was performed to investigate a
possible a role for 3D-CRT as a monotherapy for pa-
tients who refuse or could not tolerate surgical therapy
with early-stage NSCLC. In this initial study, the 1-year
survival rate for patients was 65.8 %, and the 3-year sur-
vival rate was 33.8 %. A significant difference in LC was
observed with a BED of 80 Gy or more, and the side ef-
fects were deemed acceptable. Currently, surgery is the
main treatment method for localized NSCLC, and it has
achieved favorable outcomes. The Japanese Joint Com-
mittee of Lung Cancer Registry investigated prognosis in
6644 patients who underwent resection for NSCLC by
Table 2 Univariate analysis to identify factors that affect survival
and 1- and 3-year overall survival rates
Variables p value 1-year 3-year
Age
<75 0.958 58.3 % 38.9 %
≥75 70.3 % 35.2 %
PS
≤1 0.163 70.5 % 45.7 %
≥2 33.3 % −
T-stage
T2 0.494 62.4 % 21.4 %
T3 72.9 % 48.6 %
Location 1
Lower lobe 0.250 39.4 % 19.7 %
Middle and upper lobe 81.9 % 19.0 %
Location 2
Near the pulmonary hilum 0.235 75.0 % 75.0 %
Peripheral 61.2 % 17.5 %
Pathology
Squamous 0.728 61.4 % 28.1 %
Adeno 79.5 % 53.0 %
BED (Gy)
<80 Gy 0.087 55.9 % −
≥80 Gy 76.2 % 63.5 %
Abbreviations: BED biological effective dose
Fig. 3 Comparison of local control from radiotherapy with three-
dimensional conformal radiation therapy. There was a significant
difference between patients who received a dose of <80 Gy and
those treated with a dose of ≥80 Gy (P = 0.045)
Fig. 2 Comparison of overall survival (OS) from radiotherapy with
three-dimensional conformal radiation therapy. There was no significant
difference in OS between patients with T2 and T3 non-small cell
lung cancer
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histologic type [24]. The 5-year survival rates for pa-
tients with clinical stages 1A and 1B NSCLC were 72
and 50 %, respectively. The 3-year survival rates for
those with clinical Stages 1A and 1B were 82 and 63 %,
respectively [24]. However, a limited number of patients
have operable early-stage tumors, and elderly patients
are at high risk from complications of surgery. The high
long-term costs of surgery and postoperative care justify
radiotherapy as a minimally invasive alternative treat-
ment in NSCLC [4]. In our study, the 3D-CRT outcomes
for survival was below what would be expected for
potentially curative surgery, but none the less, represent
an alternative to patients that lack a surgical option.
Conventional methods of administering radiation at a
dose of 1.8 or 2 Gy in a single fraction for a total of 60
to 66 Gy results in an LC rate of 50 % and a 3-year sur-
vival rate of 20 to 30 %, representing unsatisfactory out-
comes [6–9]. Increasing the dosage prolongs the
treatment period, which in turn results in increased pa-
tient burden and medical costs. Recent improvements in
radiation therapy techniques have led to the widespread
popularity of SBRT as an alternative therapy to radical
surgery in NSCLC. In a recent systematic review, the 5-
year survival rate in patients undergoing SBRT was esti-
mated at 47 % (range, 18–78 %) and the LC rate was
80–100 % [25]. In patients with early-stage NSCLC, it is
currently possible to achieve results comparable to those
of surgery [13]. Thus, SBRT should be considered for pa-
tients with localized NSCLC who are inoperable. SBRT
requires greater precision and accuracy than conven-
tional HFRT and 3D-CRT, and it must be performed
using a strict protocol that may not be available in all in-
stitutions [15]. A recent survey conducted in Japan re-
ported that 44 % of replying institutions did not utilize
SBRT [26]. SBRT can be deemed difficult due to varying
patient factors, such as when stable respiration is not
possible, when the tumor is close to major blood vessels
or the hilar region, when respiratory function is poor,
and when the patient is in poor general condition. In
such instances, 3D-CRT could be an alternative treat-
ment option. Despite the potential role for 3D-CRT in
the treatment of NSCLC, there have been few treatment
outcome studies. Past reports indicate that the radiation
field varies from a field encompassing the tumor plus
margin to a field in which elective nodal irradiation is
performed, and irradiation techniques and schedules dif-
fer between reports [27]. Patients with T2 or T3 NSCLC
have a higher incidence of lymph node metastasis, and
therefore, many receive concurrent anticancer agents.
Thus, irradiation monotherapy is limited to patients with
T2 or T3 cancer without lymph node metastasis, and
the irradiation field involves the tumor site only. At our
institution, a total of 525 patients received radiotherapy
for primary lung cancer during the observation period of
January 2005 to June 2014. Of these patients, 29 with T2
or T3 localized lung cancer (approximately 5.5 %) under-
went 3D-CRT monotherapy with the irradiation field set
as the tumor plus tumor margin only. We believe that
the results of the present study provide valuable data for
future 3D-CRT treatment strategies. In the present
study, the 3-year survival period following 3D-CRT for
localized lung cancer was comparable with, or better
than, those of previous reports [6, 8, 28]. This may be at-
tributed to the difference in radiation distribution. Previ-
ous reports described irradiation performed with three
Table 3 Univariate and multivariate analysis of factors that
affect local control (LC)
Variables p value Multivariate analysis
HR 95%CI p
Age (years) 0.333 0.893 0.125–6.393 0.910
<75 vs. ≥75
PS 0.023 9.773 0.778–122.7 0.077
≤1 vs. ≥2
T-stage 0.700 0.212 0.017–2.671 0.230
T2 vs. T3
Location 1 0.966 6.992 0.956–51.16 0.055
Lower lobe vs.
middle and upper lobe
Location 2 0.330 2.102 0.140–31.55 0.591
Near the pulmonary
hilum vs. peripheral
Pathology 0.505 0.303 0.034–2.680 0.283
Squamous vs. adeno
BED (Gy) 0.045 10.10 1.150–88.67 0.037
<80 Gy vs. ≥80 Gy
Abbreviations: BED biologically effective dose
Fig. 4 Comparison of local tumor control (LC) from radiotherapy
with three-dimensional conformal radiation therapy. There was a
significant difference in LC between patients with a performance
status (PS) of ≤1 and those with a PS of ≥2 (P = 0.023)
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to five portals, whereas more than five irradiation portals
are used at our institution [6, 8, 28]. The relatively small
tumor size in the present study may also have contrib-
uted to the findings, with a T staging of T2a in 18 pa-
tients and T2b in two patients. Another reason for the
findings in this study could be that patients who under-
went thorough staging by PET were included. The rea-
son that no difference in survival was observed between
T2 and T3 patients is believed to be comparable median
tumor diameter in the two groups of patients (T3,
42 mm and T2, 31 mm). It has been reported that pa-
tients with T2a (stage IB) disease who underwent SBRT
had a 3-year survival rate of 63 % [29]. Based on our re-
sults, 3D-CRT appeared to have inferior outcomes to
SBRT in patients with early-stage NSCLC. Thus, one
conclusion of this present study is that although 3D-
CRT may be a second treatment option for patients with
early-stage NSCLC who are unable to undergo SBRT, it
may not be an alternative treatment. A Japanese multi-
institutional, retrospective survey revealed that a BED
greater than 100 Gy resulted in significantly improved
patient survival and LC than a BED of less than 100 Gy
when SBRT was used to control stage I NSCLC [12].
Concerning BED, a radiation dose exceeding 100 Gy
resulted in different control rates in T1 and T2 disease,
whereas in the event of T2 lung tumors, a BED greater
than 120 Gy was required [12]. In this study, LC was sig-
nificantly improved in patients administered a BED of
80 Gy (range, 67.2–96.0 Gy). Previous reports of the use
of 3D-CRT described treatment with a 3–3.5-Gy single
fraction [16, 19]. More recently, it has been reported
that good LC has been achieved with irradiation using a
single 4-Gy fraction, and adverse events were within per-
missible ranges [20]. The total dosage is also reported to
be an important factor [30]. This study has demon-
strated that a BED greater than 80 Gy is an independent
and significant prognostic factor in LC, using a linear-
quadratic model and an α/β ratio of 10 to determine the
acute effect on tumor and normal tissues. In a previous
study using conventional fractionation, improved local
PFS was observed in a subgroup of patients with no
nodal disease who were receiving >73 Gy during 3D-
CRT [30]. The LC rate in the present study is believed
to be comparable with these earlier results. It has previ-
ously been reported that radiotherapy toxicities of CTC
Grades 3–5 develop in 20 % of patients receiving SBRT
with a single fraction that exceeds 20 Gy [31]. This same
study concluded that the regimen should not be used for
patients with tumors near the central airways because of
excessive radiation toxicity [31]. Even for SBRT using ap-
proximately 12 Gy delivered in a single fraction, a tumor
located near a major vessel or serial organ poses a concern
for the occurrence of adverse events. In the present study,
no severe adverse events (CTC Grade 2 or more) were
observed with 3D-CRT and with irradiation given at a
BED of more than 80 Gy. A previous report supports
these findings, showing that no severe adverse events
developed in 3D-CRT with a BED over 90 Gy [19]. The
results of this study support the view that to improve LC
in early-stage NSCLC, if the patient’s respiratory function
and general physical condition allow, the dose per fraction
should be increased, and if possible, the BED should ex-
ceed 80 Gy. Furthermore, because this study has con-
firmed that there are no severe radiation toxicities
associated with this regimen, it is possible that the dos-
age may be increased further. This consideration and
other aspects of the role of 3D-CRT as monotherapy in
early-stage NSCLC require investigation in further con-
trolled studies with larger patient numbers. Because of
current advances in therapy for NSCLC, as well as the
increasing numbers of patients treated with combined
anticancer agents, the number of patients receiving 3D-
CRT within one center will be limited.
Our study limitations include lack of long-term follow
up and small number of patients, because of which the
results of multivariate analysis were unclear. This limita-
tion may be addressed in the future by studies involving
multiple centers in multiple countries.
Conclusions
The retrospective nature of this study and small number
of patients who were available within a single center do
not detract from the value of these preliminary findings.
This study has demonstrated that 3D-CRT may be used
as a monotherapy for patients with T2 or T3 NSCLC as
a second treatment option for patients unable to receive
SBRT. Although the therapeutic efficacy outcomes in
this small study were inferior to those reported for
SBRT, the safety outcomes were comparable. Further-
more, to improve LC in early-stage NSCLC, this study
found that the BED should exceed 80 Gy, and it is pos-
sible that this dosage could be increased even further.
These findings support a role for 3D-CRT as a treatment
option for patients who refuse or could not tolerate surgi-
cal therapy with early-stage NSCLC, and they may form
the basis for future, larger controlled studies on 3D-CRT
as a monotherapy option for early-stage NSCLC.
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